Determination of competent virus via messenger RNA detection and tissue culture
Subject5-150 . | Location . | Day 0 . | Day 5 . | Tissue culture . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CMV (GE/mL) . | RNA IE . | RNA POL . | RNA late . | CMV (GE/mL) . | RNA IE . | RNA POL . | RNA late . | 3 d . | 10 d . | ||
H1 | Denver | 1 000 000 | POS | 1 000 000 | POS | POS | POS | POS | |||
N2 | Denver | 1 000 000 | POS | POS | POS | 1 000 000 | POS | POS | POS | POS | POS |
O2 | Denver | 110 800 | POS | 100 | |||||||
Q2 | Denver | 110 000 | POS | 351 400 | |||||||
D | Norfolk | 105 000 | POS | 468 200 | POS | POS | |||||
J1 | Denver | 97 300 | POS | 426 300 | |||||||
M1 | Denver | 93 000 | 105 200 | ||||||||
B1 | Norfolk | 64 900 | POS | POS | 506 200 | POS | POS | ||||
R1 | Denver | 60 100 | 73 100 | ||||||||
K1 | Norfolk | 49 000 | 52 800 | ||||||||
O1 | Denver | 41 200 | 100 | ||||||||
A1 | Norfolk | 36 100 | 53 300 | ||||||||
F | Norfolk | 33 100 | 41 600 | ||||||||
E | Norfolk | 26 800 | 69 100 | ||||||||
A2 | Norfolk | 24 200 | 62 800 | ||||||||
P1 | Denver | 16 700 | 56 100 | POS | |||||||
C1 | Norfolk | 16 600 | 31 900 | ||||||||
Q1 | Denver | 13 400 | 47 900 | ||||||||
J2 | Denver | 12 300 | 106 100 | ||||||||
C2 | Norfolk | 11 700 | 34 300 | ||||||||
B2 | Norfolk | 11 200 | 24 700 | ||||||||
R2 | Denver | 9 400 | 16 800 | ||||||||
G | Denver | 5 700 | 21 800 | ||||||||
N1 | Denver | 4 200 | POS | 31 300 | |||||||
H2 | Denver | 4 100 | 105 500 | ||||||||
L1 | Denver | 3 200 | 19 500 | ||||||||
L2 | Denver | 2 700 | 23 200 | ||||||||
I | Denver | 2 600 | 3 800 | ||||||||
S | Denver | 2 000 | 10 200 | ||||||||
M2 | Denver | 1 600 | 4 700 | ||||||||
K2 | Norfolk | 1 382 | 10 600 | ||||||||
P2 | Denver | 100 | 3 200 |
Subject5-150 . | Location . | Day 0 . | Day 5 . | Tissue culture . | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
CMV (GE/mL) . | RNA IE . | RNA POL . | RNA late . | CMV (GE/mL) . | RNA IE . | RNA POL . | RNA late . | 3 d . | 10 d . | ||
H1 | Denver | 1 000 000 | POS | 1 000 000 | POS | POS | POS | POS | |||
N2 | Denver | 1 000 000 | POS | POS | POS | 1 000 000 | POS | POS | POS | POS | POS |
O2 | Denver | 110 800 | POS | 100 | |||||||
Q2 | Denver | 110 000 | POS | 351 400 | |||||||
D | Norfolk | 105 000 | POS | 468 200 | POS | POS | |||||
J1 | Denver | 97 300 | POS | 426 300 | |||||||
M1 | Denver | 93 000 | 105 200 | ||||||||
B1 | Norfolk | 64 900 | POS | POS | 506 200 | POS | POS | ||||
R1 | Denver | 60 100 | 73 100 | ||||||||
K1 | Norfolk | 49 000 | 52 800 | ||||||||
O1 | Denver | 41 200 | 100 | ||||||||
A1 | Norfolk | 36 100 | 53 300 | ||||||||
F | Norfolk | 33 100 | 41 600 | ||||||||
E | Norfolk | 26 800 | 69 100 | ||||||||
A2 | Norfolk | 24 200 | 62 800 | ||||||||
P1 | Denver | 16 700 | 56 100 | POS | |||||||
C1 | Norfolk | 16 600 | 31 900 | ||||||||
Q1 | Denver | 13 400 | 47 900 | ||||||||
J2 | Denver | 12 300 | 106 100 | ||||||||
C2 | Norfolk | 11 700 | 34 300 | ||||||||
B2 | Norfolk | 11 200 | 24 700 | ||||||||
R2 | Denver | 9 400 | 16 800 | ||||||||
G | Denver | 5 700 | 21 800 | ||||||||
N1 | Denver | 4 200 | POS | 31 300 | |||||||
H2 | Denver | 4 100 | 105 500 | ||||||||
L1 | Denver | 3 200 | 19 500 | ||||||||
L2 | Denver | 2 700 | 23 200 | ||||||||
I | Denver | 2 600 | 3 800 | ||||||||
S | Denver | 2 000 | 10 200 | ||||||||
M2 | Denver | 1 600 | 4 700 | ||||||||
K2 | Norfolk | 1 382 | 10 600 | ||||||||
P2 | Denver | 100 | 3 200 |
Peripheral blood samples from 7 Norfolk subjects and 12 Denver on the day of CMV-DNAemia were further evaluated by RT-PCR forIE, POL, and late gene products on days 0 and 5 of culture. Tissue culture was performed by incubation of fibroblast with peripheral blood white cells for 18 hours and staining of fibroblast with monoclonal antibodies to IE protein and RT-PCR for IE gene products at days 3 and 10 after incubation.
See Table 1 for other abbreviations.
Number indicates first or second sample for subjects having samples from 2 separate dates tested.